Literature DB >> 29331397

Persistent hyperparathyroidism as a risk factor for long-term graft failure: the need to discuss indication for parathyroidectomy.

Maria Júlia Correia Lima Nepomuceno Araujo1, Janaina Almeida Mota Ramalho1, Rosilene Motta Elias2, Vanda Jorgetti2, William Nahas3, Melani Custodio2, Rosa M A Moysés4, Elias David-Neto1.   

Abstract

BACKGROUND: Although a successful kidney transplant (KTx) improves most of the mineral and bone disorders (MBD) produced by chronic kidney disease (CKD), hyperparathyroidism may persist (pHPT). Current guidelines recommend parathyroidectomy if serum parathormone is persistently elevated 1 year after KTx, because pHPT has been recently associated with poor graft outcomes. However, whether patients with pHPT and adequate renal function are at risk for long-term graft failure is unknown.
METHODS: Longitudinal follow-up of 911 adults submitted to KTx between January 2005 and December 2014, with estimated glomerular filtration rate (eGFR) ≥ 30 mL/min 1 year after surgery. Clinical and laboratory data were collected from electronic database. Graft failure was defined as return to dialysis.
RESULTS: Overall, 62% of the patients were classified as having pHPT 1 year after KTx. After a mean follow-up time of 47 months, there were 59 graft failures (49 in pHPT and 10 in non-pHPT group, P = .003). At last follow-up, death-censored graft survival was lower in the pHPT group (P = .009), even after adjustment for age at KTx, donor age, donor type, acute rejection, parathyroidectomy, and eGFR at 1 year after transplantation (odds ratio [OR] 1.99; 1.004-3.971; P = .049). A PTH of 150 pg/mL at 6 months was the best cutoff to predict pHPT at 1 year (specificity = 92.1%).
CONCLUSION: Having pHPT after a successful KTx increases the long-term risk of death-censored graft failure. This result highlights the need for better recognition and management of CKD-MBD before and during the first year after KTx, and opens a discussion on the more appropriate timing to perform parathyroidectomy.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29331397     DOI: 10.1016/j.surg.2017.12.010

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  11 in total

1.  Machine Learning-Derived Integer-Based Score and Prediction of Tertiary Hyperparathyroidism among Kidney Transplant Recipients: An Integer-Based Score to Predict Tertiary Hyperparathyroidism.

Authors:  Namki Hong; Juhan Lee; Hyung Woo Kim; Jong Ju Jeong; Kyu Ha Huh; Yumie Rhee
Journal:  Clin J Am Soc Nephrol       Date:  2022-06-10       Impact factor: 10.614

2.  Elevated parathyroid hormone one year after kidney transplantation is an independent risk factor for graft loss even without hypercalcemia.

Authors:  Manabu Okada; Yoshihiro Tominaga; Tetsuhiko Sato; Toshihide Tomosugi; Kenta Futamura; Takahisa Hiramitsu; Toshihiro Ichimori; Norihiko Goto; Shunji Narumi; Takaaki Kobayashi; Kazuharu Uchida; Yoshihiko Watarai
Journal:  BMC Nephrol       Date:  2022-06-17       Impact factor: 2.585

3.  Association Between Treatment of Secondary Hyperparathyroidism and Posttransplant Outcomes.

Authors:  Aarti Mathur; Whitney Sutton; JiYoon B Ahn; Jason D Prescott; Martha A Zeiger; Dorry L Segev; Mara McAdams-DeMarco
Journal:  Transplantation       Date:  2021-12-01       Impact factor: 5.385

4.  Parathyroidectomy in chronic kidney disease.

Authors:  Lillian Andrade da Rocha; Murilo Catafesta das Neves; Fabio Luiz de Menezes Montenegro
Journal:  J Bras Nefrol       Date:  2021-12-03

5.  Clinical Prediction of High-Turnover Bone Disease After Kidney Transplantation.

Authors:  Satu M Keronen; Leena A L Martola; Patrik Finne; Inari S Burton; Xiaoyu F Tong; Heikki P Kröger; Eero O Honkanen
Journal:  Calcif Tissue Int       Date:  2021-10-19       Impact factor: 4.333

6.  Mineral and bone disorder after kidney transplantation (KTx).

Authors:  Carolina Lara Neves; Igor Dernizate B Marques; Melani Ribeiro Custódio
Journal:  J Bras Nefrol       Date:  2021-12-03

7.  Prevalence and risk factors for tertiary hyperparathyroidism in kidney transplant recipients.

Authors:  Whitney Sutton; Xiaomeng Chen; Palak Patel; Shkala Karzai; Jason D Prescott; Dorry L Segev; Mara McAdams-DeMarco; Aarti Mathur
Journal:  Surgery       Date:  2021-07-12       Impact factor: 3.982

8.  Surgery for Renal Hyperparathyroidism in the Era of Cinacalcet: A Single-Center Experience.

Authors:  M T Mogl; T Skachko; E M Dobrindt; P Reinke; C Bures; J Pratschke; N Rayes
Journal:  Scand J Surg       Date:  2020-01-06       Impact factor: 2.360

9.  Disrupted tubular parathyroid hormone/parathyroid hormone receptor signaling and damaged tubular cell viability possibly trigger postsurgical kidney injury in patients with advanced hyperparathyroidism.

Authors:  Tetsuhiko Sato; Yamato Kikkawa; Suguru Yamamoto; Yusuke Tanaka; Junichiro J Kazama; Yoshihiro Tominaga; Toshihiro Ichimori; Manabu Okada; Takahisa Hiramitsu; Masafumi Fukagawa
Journal:  Clin Kidney J       Date:  2019-01-28

10.  Parathyroid surgery during the COVID-19 pandemic: Time to think about the "New Normal".

Authors:  Fábio Luiz de Menezes Montenegro; Marília D'Elboux Guimarães Brescia; Sergio Samir Arap; Marco Aurélio Valmondes Kulcsar; Marcos Roberto Tavares; Luiz Paulo Kowalski
Journal:  Clinics (Sao Paulo)       Date:  2020       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.